Vericel (VCEL) Asset Utilization Ratio (2012 - 2026)

Vericel (VCEL) posted Asset Utilization Ratio of 0.62 for Q2 2026, up 3.29% sequentially from 0.6 in Q1 2026, and up 7.0% YoY from 0.58 in Q2 2025.

Analysis

Vericel (VCEL) Asset Utilization Ratio (2012 - 2026) Analysis & Trends

Vericel has reported Asset Utilization Ratio for 15 years, with the latest figure at 0.62 in Q2 2026.

Quarterly Asset Utilization Ratio rose 7.0% year-over-year to 0.62 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.62 (up 7.0% YoY) and the FY2025 annual result came in at 0.6, down 0.53% from the prior year.
Asset Utilization Ratio rose to 0.62 in Q2 2026 per VCEL's latest filing, from 0.6 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.65 in Q1 2022 and troughed at 0.56 in Q1 2025.
A 5-year average of 0.6 and a median of 0.59 in 2023 frame the typical range for Asset Utilization Ratio.
The sharpest annual moves came in 2023 and 2026: Asset Utilization Ratio fell 8.86% in 2023, then rose 7.82% in 2026.
Over 5 years, Asset Utilization Ratio stood at 0.63 in 2022, then declined by 6.8% to 0.59 in 2023, then retreated by 1.98% to 0.58 in 2024, then advanced by 1.84% to 0.59 in 2025, then advanced by 5.58% to 0.62 in 2026.
According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.62, 0.6, and 0.59 for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.38
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.20
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.69
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	0.90
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.13
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.54
10	Vericel	2.05 Bn	1.89 Bn	56.40 Mn	0.62

Historic Data

Download Data